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Amyloid-based nanosensors and nanodevices
Charlotte A. E. Hauser,*a Sebastian Maurer-Strohb and Ivo C. Martins*c
Self-assembling amyloid-like peptides and proteins give rise to promising biomaterials with potential
applications in many fields. Amyloid structures are formed by the process of molecular recognition and
self-assembly, wherein a peptide or protein monomer spontaneously self-associates into dimers and
oligomers and subsequently into supramolecular aggregates, finally resulting in condensed fibrils. Mature
amyloid fibrils possess a quasi-crystalline structure featuring a characteristic fiber diffraction pattern and
have well-defined properties, in contrast to many amorphous protein aggregates that arise when proteins
misfold. Core sequences of four to seven amino acids have been identified within natural amyloid
proteins. They are capable to form amyloid fibers and fibrils and have been used as amyloid model
structures, simplifying the investigations on amyloid structures due to their small size. Recent studies have
highlighted the use of self-assembled amyloid-based fibers as nanomaterials. Here, we discuss the latest
advances and the major challenges in developing amyloids for future applications in nanotechnology and
nanomedicine, with the focus on development of sensors to study protein–ligand interactions.
1. Introduction
Nanotechnology offers exciting opportunities for the development
of advanced biomaterials. Nano-sized biological entities and
chemically defined compounds can be used as building blocks to
engineer devices and substrates with desired physico-chemical and
biomimetic properties.1–9 This has already promoted major break-
throughs leading to new nanomaterials and nanodevices.1,3,7,10
The majority of the current materials exploited for nanotechnology
is based on classical polymeric systems, on which a multitude
of publications has been issued in recent years and reviewed
elsewhere.9,11–19 The main objective of this article is to foster a
greater understanding of the less exploited amyloid-based
materials. The term amyloid, referring to the Greek word for
starch, was first coined by German botanist Matthias Schleiden
for starch-like material in plants and later applied to deposited
aggregates in the brain by German pathologist Rudolph
Virchow. Virchow was originally convinced that these brain
deposits were from starch or cellulose origin.20 Our emphasis
in this review is on amyloids, which are structures that self-
assemble from protein and peptide monomers into cross-beta
structures and are defined by a characteristic fiber diffraction
pattern. Pioneering work on the determination of the ordered
structure of amyloid fibrils by X-ray fiber diffraction analysis
was done by Louise Serpell and colleagues.21–24 Since amyloids
are generally derived from natural proteins, they have a low
immunogenic and inflammatory potential, due to their intrinsic
biocompatibility.2,8,25–28 Earlier studies have demonstrated that
highly ordered amyloid cross-beta structures are associated
protein-specific amyloid core sequences of four to seven amino
acids.29–32 The core sequences are able to self-assemble into
structurally highly similar fibrils that resemble the fibrils derived
from the entire protein. Therefore, they are willingly used as
model systems, because they simplify the studies on amyloido-
genesis due to their substantially shorter size.29–31,33,34 Based on
the existing structural knowledge, it would theoretically be
possible to create novel peptides that form amyloids, simply by
using Nature’s diverse toolbox. In practise, this has been proven
to be challenging. Although prediction tools are available, the
prediction of the potential of a given peptide sequence to form
amyloid fibers is not satisfactory. Thus, continuous improve-
ments are needed. In particular, we want to point out that not
every reported amphiphilic peptide that forms b-sheets by self-
assembly is evidentially an amyloid structure.35,36 Known amyloid
peptide motifs can be combined with lipids, nucleic acids,
sugar moieties and other building blocks. In addition, synthetic
moieties will expand chemical versatility and functionalization
potential. In particular, amyloid core sequences or very short
amyloid-like peptides containing only a few amino acids have
been exploited for technical applications. The most inspiring
feature of these novel materials and devices is their short size.
The current level of proficiency for understanding the mechanism
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of self-assembly of amyloid-like peptides and proteins at the
nanoscale is rather limited. Nonetheless, the existing knowledge
already allows the design of defined nanomaterial and nanodevices
in dimensions down to atomic level accuracy. For example, the
structure of amyloid fibers from the protein transthyretin (TTR)
has recently been determined at an unprecedented 0.5 Å
atomic-resolution.37 Already earlier, other structures of amyloid
fibers, close to atomic-resolution, had been reported.24,31,32,37–43
The nano-range dimensions constitute a key advantage, since
their scale roughly matches the size of biological molecules,
allowing promising developments.10,44,45 It encompasses
the study and monitoring of individual biomolecules under
biologically relevant conditions.45–47 It is now possible to track
a biomolecule, such as a protein, in its biological context,
for example when it interacts with a ligand inside a cell.47,48
Developing this further by employing biocompatible materials,
while simultaneously lowering the threshold at which protein–
ligand interactions are detectable, will lead to further advances.
We discuss the possibility of using amyloid-based nanomaterials
as tools to detect protein–ligand interactions and cover future
applications in nanotechnology and related fields, such as bio-
nanoelectronics.
1.1. Major requirements of novel biomaterials
The rapidly expanding field of nanotechnology requires devices
that achieve high levels of complexity and control of micro-
environment on a molecular scale.49 The current state-of-
the-art in micro- and nanofabrication technology allows the
construction of nanodevices in very small dimensions and the
creation of different topologies.50–59 Multitudes of techniques
are now used for the construction process, although the field
has not yet reached sufficient maturity. Commonly used methods
require modification of a substrate via several processes such as
thin film deposition (an additive process to the substrate), pattern
transfer lithography (also an additive process to the substrate),
selective etching (an ‘‘erosive’’ process of the substrate) and
injection-moulding (which can be applied onto silicon, glass or
polymer substrates).60–65 The disclosed methods can also be
combined. Using micro-channels, through which a flow of a given
substance can be passed, add an additional dimension to the
devices by allowing the flow speed, the liquid composition, and
other parameters to be modified in a controlled and well-
established manner. All this put together has led to the popular
lab-on-a-chip (LOC) concept, where the major goal is to build a
completely automated and sensitive biosensor system on a small
portable chip.66 Biological nanostructures, in particular self-
assembling peptide nanostructures, have been shown to exhibit
promising features that make them suitable for the fabrication of
LOCs and microfluidic devices. Different to nanomaterial such as
carbon-based nanotubes or silicon nanowires, the self-assembling
peptides are used under mild fabrication conditions. Further-
more, the peptide fiber fabrication process is much faster, less
costly and does not require a clean-room.67–71 Ideally, scaled-
down systems can perform as many operations as those currently
conducted in a standard-size laboratory, but with lower sample
volumes, shorter analysis times and reduced costs. All the
mentioned systems can be applied for the accurate detection
and quantification of biological molecules in small samples
which will have an impact on drug discovery strategies, on food
and water quality, on research-related applications and, finally,
on clinical diagnostics. There is no doubt that nanotechnology
offers smart tools that will circumvent complex and bulky
infrastructure in the laboratory and that future advances will
rely on such fast and easy-to-use LOC devices. However, to
guarantee successful developments, further technological
improvements are needed, such as lower threshold levels at
which biological species are detected. This will enable sensitive
detection of rare biochemical analytes and influence the signal
to noise ratio, as will be discussed in the following sections.
1.2. Recent progress of the lab-on-a-chip system
Successfully engineered highly sensitive ‘‘lab-on-a-chip’’ devices are
a major goal in the development of microfluidics biosensors.63,72
Three major steps are required to proceed in a controlled fashion
within the confined space of the microchip, namely: (i) the
handling of the species in terms of fluidics, (ii) the occurrence
of the biological phenomena under study and (iii) the sensing
(i.e., the detection) of the occurrence of the biological phenomena.
Regarding the first step, the handling of the species, it comprises
the actual design of the chip, in combination with the flow
channels schematics, the engineering of the flow paths and
the method(s) of controlling the flow parameters. There is no
question that this is the key step of any approach aiming to
construct a lab-on-a-chip biosensor. The second step, the
detection of the biological event, is somewhat simpler, since
different approaches can be followed. The most successful
procedure involves the use of optical and electrochemical
sensors and will be discussed later on. Concerning the last
step, the sensing, the biological event under study can range
from simply determining and quantifying the presence of a
biomolecule (such as a nucleic acid or a protein) up to the
development of cell-chips for the analysis of protein–ligand
interactions. For a perfect chip, the first stage (fluidics) is
essentially independent from the next two steps and easily
adaptable to different biological problems under study.
Furthermore, shortening or merging the last two steps, i.e.,
the biological event step and the detection step, is an important
move forward, given the possibilities it opens in terms of
simplification of the chip design. Regarding self-assembled
peptide nanostructures, the diphenylalanine (FF) dipeptide
and its aromatic dipeptide analogue, the tert-butyl dicarbonate
Boc-FF, have been extensively investigated for the development of
LOC and microfluidic devices.68–70 Depending on the fabrication
process, different nanostructures, such as nanotubes, nanowires
and nanoparticles can be created. The main advantage of the FF
peptide structures that makes them suitable material for nano-
fabrication is their strong mechanical properties, their resistance
to proteolytic, thermal and chemical manipulations. Their
stability under liquid conditions, when using them in organic
or aqueous environments, and the ease of overcoming the low
innate conductivity of these peptide nanostructures by applying
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them as etching masks or doping them with conductive material,
suggests their usefulness for nanosensor developments.68–70
1.3. Commonly used nanomaterials
The most commonly used nanomaterials are carbon-based
materials, such as carbon nanotubes. Also metal nanoparticles
and quantum dots are widely exploited nanomaterials.73–78
Nanomaterials applied to electrochemical or optical immunoassays
have been utilized in the detection of biomolecule activity.8,9,79,80
Carbon nanomaterials, such as carbon-based nanotubes and nano-
fibers, have been amply discussed in the context of their aptness for
the development of nanosensors. They all feature a number of
characteristics, such as biocompatibility, chemical functionality
and conductivity, which are suitable for the detection of biological
interactions. They are especially useful for ultrasmall volumes and
very low concentrations of solutes. In particular, carbon nanotubes
have been investigated for the detection of biomolecules, namely
cytochrome c, hydrogen peroxide and nicotinamide adenine dinu-
cleotide, demonstrating their great potential for the development of
detection kits and other similar approaches.81,82 Recently, carbon
nanotubes have been reported to induce inflammation in in vivo
applications, in particular lung inflammation and fibrosis.83
Hence, their practicability might be somewhat limited.
Nanoparticles are giving alternatives for the study of biomolecules
but they also have some drawbacks. A recent investigation observed
strong interactions of nanoparticles with proteins from biological
fluids, derived from living systems, showing that the protein-coated
nanoparticles were critically affected in their mode of action and
pathophysiology.84 In spite of this, nanoparticles are frequently used
as labels, markers or probes, to report on the presence and activity of
a given biological molecule. They can be composed of colloidal
metals (gold or silver) in conjugation with a bioactive molecule (DNA,
protein, antibody). In such a set-up, the biomolecule provides
specificity for the analyte to be investigated, while the metal enables
the interaction to be detected. Quantum dots represent a variation
of the colloidal metal-based nanoparticles. Here, the metal is sub-
stituted by inorganic crystals (group II–VI or III–V elements) or silica,
with the same final objective, to be successfully employed in different
biomedical applications.
It is anticipated that nanoparticles and carbon-based nano-
materials will continue to play a major role in the developing
field of nanotechnology. However, there is an ongoing search
for novel materials in order to overcome the restrictions that
they inherently possess. Briefly, regarding carbon-based nano-
materials, such as nanotubes, it is important to keep in mind that
these structures, besides their inflammation potential, are essentially
composed of one or more concentric tubes of graphite. As a matter
of fact, these tubes are relatively fragile. The same problem applies
for standard carbon nanoparticles. Their resistance to the surround-
ing environment and their ability to allow for chemical reactions to
occur in the proximity is comparatively reduced. The fragility is
certainly an additional specification that is inconvenient for many
applications. There is clearly a demand for other materials that
overcome these limitations. Ideally, novel materials should effort-
lessly integrate with the current technologies while also providing
novel features that can be exploited for innovative applications.
One of the possibilities is the use of amyloid-based nanomaterials.
Amyloids are generated during amyloidogenesis. They can be
observed when peptides and proteins aggregate. The amyloid fiber
structures have been extensively studied and characterised, as earlier
mentioned, but the mechanism of amyloidogenesis is still unclear.
Since only the final structures, the amyloid fibers, will be employed
as nanomaterial, the precise control over each step during fiber
formation is less important. Given the fibers’ well-established prop-
erties, the fabrication of fascinating nanomaterials from amyloids
for nanotechnology research is easy to imagine.
2. Amyloidogenesis
The use of amyloids as nanomaterials to probe interactions
between biomolecules is highly beguiling.1–9 It implies that the
size of the amyloid nanomaterial matches the dimensions of
the molecules under analysis. Thus, using amyloid nanomaterials
for analytical purposes should provide the maximum possible
degree of miniaturization and simultaneously minimize the use of
reagents and samples. Ideally, amyloid nanomaterials with
unique chemical and physical properties, as to size, composition,
conductivity, magnetic properties, mechanical strength, light
absorbing and emitting properties, should be engineered without
any problems. Assuming that the amyloid nanomaterials fulfil
all the desired criteria, they should hit the mark of detecting
nanoscale protein–ligand interaction and selecting low level
biomolecule analytes. Simultaneously, they should be adaptable
for the analysis of other biomolecules with minimal change in
the biosensor design. A further requirement for relevant amyloid
biosensor nanomaterials is their resistance to the surrounding
milieu. Thus, when chemical reactions take place in the immediate
vicinity of the nanomaterial, they should not affect it. Furthermore,
the possibility to chemically modify the amyloid nanomaterial for a
specific function without affecting the chemical and mechanical
stability is of utmost importance. For some applications, it is
also desirable to have amyloid nanomaterial that self-assembles
in a well-established and ordered manner to provide distinct
topographies. Thus, it is of particular interest to define strategies
for controlled self-assembly and surface patterning when using
amyloids. In fact, amyloid fibrils exhibit exactly these features.
Under most biological conditions amyloids are not strongly
affected by the environment and can be chemically modified
for a specific function. For this reason, amyloid materials are
becoming attractive tools in nanotechnology research. However,
uncertainties about amyloids’ biological activity and potential
toxicity have hampered further use of amyloid fibrils in nano-
technology. In order to give more clarity and to avoid this
misconception, the state-of-the-art is briefly discussed in this
section, highlighting our current understanding of amyloidogenesis
and the different structural entities involved.
2.1. Amyloidogenesis: a highly organized protein–peptide
aggregation process
The mechanism of amyloidogenesis is still a mystery, but
remains of foremost interest manifested by its implication in
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the onset of debilitating degenerative diseases, such as Alzheimer’s,
Parkinson’s, ALS, Creutzfeld–Jakob and diabetes type II disease,
besides many others.85–88 It is less known that amyloids are also
involved in non-pathological events. These amyloids, also named
‘‘functional amyloids’’, seem to exert regular biological functions.
Functional amyloids are found within all type of species, from fungi
and bacteria to insects and mammalians. Hence, it is very likely
that the amyloid structure provides an important structural feature
in the morphogenesis of a species. Peptide hormones are for
example stored in secretory granules in an amyloid-like cross-
beta-sheet conformation.89 It has been proposed that reversible
amyloid-like nanofibrils are the inherent structural forms of stored
peptide hormones.90 Other examples for functional amyloids
in humans are amyloid fibers that serve as templates for the
biosynthesis of melanin.91–93 Furthermore, it has been shown that
human serum albumin, lysozyme and other native proteins have a
predisposition under certain situations to give way to amyloid fibril
structures.94,95 It is conceivable that the transition of a non-fibrillar
protein to a self-aggregated amyloid fibrillar state does not
necessarily only play a role in disease pathogenesis but also
has a key function in signalling, communication and memory-
storage. Examples for the latter events have been reported for
bacteria in their formation of biofilms as a way to communi-
cate.96–98 For prion amyloids it was demonstrated that they
might be essential for the storage of memory in the brain.99
There exists a variety of hypotheses, aiming to explain the
process of amyloid formation with the misfolding theory as
the most prominent example.100–102 As a matter of fact, there
is confusion regarding how initiation and progression of the
process occurs, whether it involves exclusively larger poly-
peptides or proteolytically degraded smaller-sized core sequences
that steer the event.103 The adopted view of a disordered nature
of the process of amyloidogenesis and the variety of species
found in solution could explain some of the reluctance in
nanotechnology developments to use amyloid fibrils. Therefore,
we would like to stress the fact that at least all final amyloid
structures, although being unrelated in respect to sequence,
function and species, have the same distinct X-ray fiber diffrac-
tion pattern.21,104,105 The characteristic diffraction pattern that
serves as the hallmark for amyloid designation is pointing to an
orderly arranged end structure that assumingly could be
explained by a highly organized self-assembly process. The
complexity of controlling the amyloid formation process is most
likely due the early stages where heterogeneous populations of
precursors and oligomeric states appear next to each other.
Any efforts employing amyloids as nanomaterials and taking
advantage of their self-assembling properties require an under-
standing of amyloids’ properties and of the structural features of
the species found during amyloid fibril formation. It is impor-
tant to keep in mind that amyloidogenesis is not a simple two
state process. A multitude of intermediate species can be found
between the initial monomeric peptide–protein sequences and
the final mature amyloid fibril. The variety of species found has
led to a number of different notations for these intermediates. In
the case of the amyloid beta peptide, intermediate species have
been designated as oligomers, protofibrils, annular assemblies
and diffusible ligands. For simplicity, in this article, the inter-
mediate species will be referred to as oligomers/protofibrils,
which facilitates the description while it still reflects the variety
of species observable. In this view, amyloidogenesis can be
described as an ordered process where monomers lead to
oligomers/protofibrils that then convert themselves into the
mature amyloid fibrils, as described in Fig. 1.35,106–108 For the
sake of clarity, throughout the text, the schematic drawings of
amyloidogenesis processes depict monomer arrangements
describing inter-molecular interactions. We also opted for
employing mostly a depiction of anti-parallel beta-sheet arrange-
ments. This necessary simplification of the amyloidogenesis
processes allows, hopefully, for the reader to more easily under-
stand the key messages in each drawings.
For the application of amyloid fibers in nanotechnology it is
important to consider the kinetics of amyloid fibril formation
and the dependency on nucleation seeds.109–114 In short, the
presence of pre-assembled oligomers/protofibrils, which can
act as nucleation seeds, greatly accelerates the process. Pre-
assembled oligomers/protofibrils eliminate or shorten the lag
phase during which monomers slowly self-assemble into
higher order aggregates. Monomers rapidly proceed into
mature fibrils in a very fast manner via monomer addition to
the nuclei. Hence, any amyloid-based nanotechnology
approach must factor into account the possibility that multiple
oligomeric species may simultaneously be present and that the
kinetics of the process can vary due to the initial conditions.
2.2. Amyloid fibrils: highly ordered cross-beta structures
Several key findings helped to shape our current understanding
of amyloid fibril structure.35,85,100,101,105,107,108,115–118 Transient
aggregation was observed in several proteins, and even in
inclusion bodies, suggesting an ordered simultaneous formation
and re-solubilisation of aggregates. Spectroscopy studies identified
two major types of aggregates: aggregates, where the formation of
beta-sheets is involved and, to a lesser extent, aggregates that retain
a native conformation. Interestingly, both can eventually evolve into
amyloid fibrils invariably rich in cross-beta structure, as elucidated
in Fig. 2.
It is noteworthy to mention that the formation of beta-sheet
rich aggregates does not automatically imply the generation of
amyloid fibrils. Amyloid fibrils however typically contain a
high content of beta-sheet structures and require the formation
of beta-sheet rich precursor aggregates.117 The self-assembly
process (during which conformational change(s) occur) ends in
the typical beta-sheet enriched amyloid fibril structure.
Detailed characterization of amyloid fibril structure suggests
that fibrils are in a cross-beta arrangement, where tightly
packed beta-sheets orientate themselves perpendicularly to
the fiber elongation axis. Intra- and intermolecular hydrogen-
bonding, salt bridges, solvent effects as well as stacking of the
sheets with potentially occurring aromatic side-chains are most
likely the main factors that stabilize the mature fibril structure.
The rigid arrangements could explain the stability of amyloid
fibers in aqueous solutions and support well their use in
nanotechnology.
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2.3. Amyloid toxicity: pathological fibrils precursors versus
physiological mature fibrils
The use of amyloids as nanomaterials was partially delayed due
to several misconceptions. A very common misunderstanding
relates to the toxicity of amyloid fibrils. It is a result of their
initial characterization as toxic species in studies, focussing
on the debilitating degenerative amyloid diseases, such as
Alzheimer’s and Parkinson’s disease among others. Since fibril
formation was first observed in these diseases, it was initially
erroneously assumed that the fibrils were the cause of toxicity.
In fact, in later studies the precursor intermediates of the fibrils
were classified as the cause of toxicity, while the mature fibrils
in physiological conditions were found to be relatively benign
and innocuous.96 This widespread misperception has certainly
hindered the exploration of the promising technological applica-
tions of amyloid fibrils. Another commonly found misconception
relates to the view of amyloid fibrils to exert no function. Since for
a long period of time no clear physiological role for amyloid fibrils
was found, it was initially assumed that these are not likely to
perform any function, constituting what could be called a ‘‘wrong
turn’’ in the protein folding pathway. In fact, amyloid fibrils
perform a number of physiological roles, such as serving as
extracellular matrix materials of bacteria, as essential amphipathic
materials of fungi and bacteria, as protective envelops of fish and
insect eggs, and as the essential nanowire component of spider’s
Fig. 2 Different amyloid fibril structures. Amyloid fibrils can self-assemble
both into a (a) parallel as well as an anti-parallel arrangement (shown in
panel (a) of Fig. 1). The schematic drawings of parallel and anti-parallel
amyloid monomer arrangements depicted here are used as simplified
examples to facilitate the understanding of the main text. (b–l) Crystal
structures of several amyloid Ab segments, shown in projection down the
fiber axes, with the Ab segments packed as pairs of interdigitated b-sheets
(the basic unit of the fibril) and displaying b-sheet structures composed of
parallel strands (e, g, h, l) and of antiparallel strands (b–d, f, i–k) (adapted
with permission).117
Fig. 1 Main features of amyloidogenesis. (a) Amyloidogenesis is a highly
ordered nucleation-dependent process, where monomers give rise to
intermediate structures (oligomers/protofibrils) that later give rise to the
mature amyloid fibril. It is important to clarify that the schematic drawing
of an antiparallel amyloid monomer arrangement is only used as a
showcase, since there are parallel monomer arrangements possible as
well. (b) Irregular protein aggregates and (c) amyloid fibrils are clearly
distinct. Reprinted with permission.35 (d) Mature amyloid fibrils are invariably
rich in b-turn structure (adapted with permission),106 in contrast to other
irregular protein aggregates, showing (e) quasi-crystalline amyloid fibrils
with highly ordered cross -beta structures (adapted with permission).108
(f) In most amyloidogenic sequences that are associated with diseases, for
example the Alzheimer’s-related amyloid beta peptide 42 sequence, the
toxicity of amyloid fibrils is found to be associated with the fibril precursor
aggregates (oligomers/protofibrils) and not with the mature amyloid fibrils
(adapted with permission).107
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silk. Furthermore, functional amyloids have vital functions like
skin pigmentation in mammals, including humans, where an
amyloidogenic sequence plays a key role as a vital scaffold for
melanin biosynthesis,91–93 depicted in Fig. 3.
The formation of melanin in the human melanosome occurs
via the interplay of small reactive molecules, precursors of
melanin, and an amyloid sequence. In brief, the melanin
precursor (MP) is activated by a tyrosinase (T) resulting in the
activated melanin precursor (AMP) which then interacts with
the amyloidogenic sequence PmeI17 (PmeI) to form mature
melanin. The amyloid sequence PmeI drives a fast amyloid
formation process: mature melanin is formed with PmeI serving as
a template that organizes the melanin precursors and accelerates
the covalent polymerization of these molecules into the mature
melanin molecule.91–93 Amyloidogenic protein sequences have
been suggested to play other physiological roles, namely involving
fibrin and tissue-type plasminogen activator. Fibrin results from
thrombin-mediated proteolysis of fibrinogen. Fibrin is primarily
involved in blood clotting and platelet activation mechanisms,
regulated by tissue-type plasminogen activator, which is a regulator
of fibrin clot lysis.119,120 Interestingly, several amyloidogenic
peptides, namely amyloid beta-peptide and fibrin-derived
amyloidogenic sequences interact with tissue-type plasminogen
activator,120 suggesting additional roles for amyloidogenic
sequences in the modulation of the activity of other biomolecules.
Furthermore, amyloid conformers of endostatin were reported to
possess anti-angiogenic activity.121–123 All these findings clearly
indicate that amyloidogenesis plays an important physiological
role in different organisms, including humans.
3. Amyloid fibrils in nanotechnology
The variety of physiological functions of amyloid fibrils
exploited by Nature reveals their harmless potential for nano-
technology. Furthermore, the stability and reduced cytotoxicity
of the mature pathological fibril found in degenerative diseases
(when compared to the fibril precursor, the protofibril) is an
important information. In addition, their recognized diversity
and the fact that they are well-characterized in terms of
structure and formation explain the current interest in these
structures. Several applications are under scrutiny, with the
most promising ones using amyloids as potential nanowires for
electronics, as functional templates and liquid crystals, for the
production of amyloid-based gels in cell adhesion and wound-
healing, and as drug delivery systems.
3.1. Amyloid-based drug delivery
The conjugation of peptides–proteins with drug compounds is
a useful strategy to create long-acting drug depots and to
overcome some of the limitations related to the use of the
individual drugs alone, such as premature enzymatic degrada-
tion or limited blood circulation and bioavailability.124 Amyloid
fibrils of insulin have been shown to possess a large void space
able to accommodate molecular iodine. Iodine molecules seem
to be solvent accessible and can eventually be released. Thus,
insulin-based amyloid fibrils may potentially provide a model
for the design of protein-based drug delivery media.125 In case
that the drug by itself self-assembles to amyloid structures,
as was found for gonadotropin-releasing hormone (GnRH)
analogues, it is possible to formulate such amyloids as stable
drug depots that offer a controlled release of the active drug
from the amyloid conjugate.126 This concept was demonstrated
for a family of short-and long-acting analogues of GnRH,126
Verified by electron microscopy the long-acting GnRH-
analogues formed amyloid-like fibrils and manifested a wide
variety of morphologies. Moreover, the duration of action of
release depended on the ability of the GnRH analogue amyloids
to slowly release active peptide, supporting the role of amyloids
as drug depots. These findings were supported by in vitro and
in vivo tests, which also showed that these amyloid fibrils were
not toxic to dermal cells. Based on the current understanding
of the amyloidogenesis process and on experimental data
currently available,89,126 a generic amyloid-based drug delivery
system is depicted in Fig. 4.
Recent studies support the use of amyloids as drug-delivery
systems. The therapeutic antibody-derived candidacidal deca-
peptide (killer peptide, KP) was shown to spontaneously and
reversibly self-assemble into fibril-like structures.127 Since this
self-assembled amyloid state may avoid proteolysis but still will
slowly release the active dimeric peptide form over time, it can
also serve as a drug delivery system. Recently, another micellar
nanocontainer delivery and release system has been designed
employing a peptide–polymer conjugate of hybrid molecules
which self-assembles into micelles comprising a modified
amyloid peptide core surrounded by a poly-ethylene glycol
(PEG) corona.128 In the peptide–PEG hybrid system studied,
enzymatic degradation, using alpha-chymotrypsin, leads to
selective cleavage close to the PEG–peptide linkage. Then the
break-up of the micelles and the release of free active peptides
follow. The trade-off between possible amyloid toxicity and
drug delivery potential seems to favour the later, encouraging
further research along this concept. Also, the FF dipeptide,
Fig. 3 Physiological relevant amyloid fibril formation. Amyloids were
initially considered the pathological outcome of a misfolding event, but
it is now clear that amyloid fibrils can have physiological functions, such as
in melanin synthesis in the human melanosome. Briefly, the melanin
precursor (MP) is activated by a tyrosinase (T) resulting in the activated
melanin precursor (AMP), which interacts with the amyloidogenic
sequence PmeI17 (PmeI) leading to mature melanin.91–93














































5332 | Chem. Soc. Rev., 2014, 43, 5326--5345 This journal is©The Royal Society of Chemistry 2014
assembled to microtubes, has been explored for effectively
deliver drugs. Using rhodamine as a model drug, it was shown
that the FF microtubes released the drug in a steady-state
profile, following first-order kinetics. Applying the microtubes
to erythrocytes and fibroblast cells, had no impact on cell
viability, demonstrating the potential of these carriers to deliver
drugs at a constant rate.129
3.2. Amyloid nanowires and nanotubes
Since amyloids tend to self-associate into organized fibrils, the
first nanotechnology applications investigated were related to
the design of nanowires and nanoelectronic materials. This
approach was very successful. Using peptides combined with
metals or enzymes, it was possible to produce artificially
engineered peptide/protein-based nanowire structures. Reches
and Gazit first demonstrated that the diphenylalanine dipeptide
structural motif, also found in b-amyloid, could form rigid
nanotubes that, after reduction of ionic silver within the nano-
tubes and proteolysis of the peptide results in the formation of
nanowires.130 Furthermore, Gazit and coworkers were able to
control the challenging task of an aligned arrangement of FF
nanotubes on self-assembled arrays by the vapour deposition
technique, as shown in Fig. 5.131
With this attractive technology, the number, length and
density of the nanostructures can be carefully tuned by simply
adjusting the amount of peptide building blocks in the gas
phase. Thus, self-assembling peptides can be employed as
promising nanomaterials for the construction of ultracapacitors
to store energy.131 In future, it is conceivable that on the basis of
this technology large-scale arrays of arranged peptide nanotubes
or nanowires will be fabricated which then can be utilized as
high-surface-area electrodes for energy storage applications, for
microfluidic devices and for smart surfaces with favourable self-
cleaning abilities due to their highly hydrophobic properties.
Several other groups have investigated FF nanotubes
for different nanofabrication purposes exploiting their strong
stiffness and their stability under defined conditions, as for
example Castillo-León, Svendsen and colleagues. They looked
into the electrical properties of FF nanotubes,132 and explored
applications, using FF nanotubes as etching material,133 or for
the fabrication of silicon wires134 and as electrode material for
biosensor development, in particular for the fabrication of
PEDOT nanowires.135 Recently, Reches and colleagues were able
to self-assemble the aromatic FF dipeptides and its Boc-protected
analogue into either tubular or spherical structures and obtain
various morphologies from these self-assembling peptides, which
complement the classical amyloid fibril structure, as shown in
Fig. 6.136
Briefly, when both structures were put together, they
co-assembled to interesting necklace or beaded string structures
under reversible and stable conditions.136 Using this strategy, one
can imagine a large variety of novel, complex mixed structures.
Decoration of these co-assembled chains with biological entities,
such as enzymes, antibodies and other bioactive moieties or with
chemical cues opens up enormous opportunities for sensor, drug
delivery and tissue engineering applications. Hence, employing
self-assembling peptides will also support the exploration of
other morphologies that go beyond and complement the well-
established fibril structure. In addition to that, a novel direction
has been taken by using FF dipeptides for the fabrication of
biomimetic artificial motors, as described in Fig. 7.137
Here, the biomimetic hybrid motor system contains a
metal–organic framework (MOF) together with the FF peptide.
MOFs made of metal ions and bridging organic ligands are
nanoscale porous materials that have been proposed as motor
systems due to their rigidity, density and distinct pore size. The
FF peptides assembled in the highly ordered pore array of the
MOFs. When the assembled peptide structures got released
from the MOF, a swimming motion was initiated due to a large
Fig. 4 Amyloid fibrils as slow drug release systems. In a simple setting,
amyloid monomers (blue arrows) may entrap the drug (D) within the
mature amyloid fibrils during the amyloidogenesis process. Afterwards,
this conjugate may be safely transported to the vicinity of the drug
molecular target (T). The drug can then be slowly released to perform its
functional binding to its molecular target.
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surface tension difference around the MOF. The authors envision
new applications towards smart autonomous motors that might
mimic swimming bacteria, and with integrated recognition sites,
might harvest targets, such as toxic chemicals. Scheibel and
colleagues showed that N-terminal and middle region (NM)
amyloid fibrils of wild-type Sup35p, a prion determinant of
S. cerevisiae, were stable under varying harsh conditions. Most
importantly, they manipulated the fibril length according to the
assembly conditions, making amyloid fibrils ranging from 60 nm
to several hundred micrometers in length.48 Moreover, by mutating
one lysine to a cysteine, the resulting sequence assembled to
amyloid fibrils that were able to covalently bind to gold nano-
particles. When placed on gold electrodes and further chemically
treated with silver and gold, a hybrid gold–silver nanowire of a
diameter of 100 nm was produced that could effectively conduct an
electrical current. This is the first example of a regular solid metal
wire fabricated from amyloid peptides–proteins that could properly
be called a nanoscale electrical circuitry, i.e., an amyloid nanowire.
Herland and colleagues produced an electronically active lumines-
cent nanowire by combining insulin-derived amyloid fibrils with
the PFF polymer. This could be employed as an active layer in a
light emitting diode with quantum efficiency greater than a similar
construct without the amyloid species included.138–140 Subse-
quently, Hamedi and colleagues reported the formation of amyloid
fibrils, using insulin coated with polymer alkoxysulfonate (PEDOT).
This resulted in the construction of a functional electrochemical
transistor operating at low voltages between 0 and 0.5 V.141 Further
advances will require small sized circuits and a number of different
possible applications to be investigated. Exploring the limits of the
technology, Malisauskas and colleagues managed to form ultrathin
silver wire of 1 nm diameter and up to 2 mm in length using
lysozyme amyloid fibrils with hollow channels filled with
silver.142 Barrau and colleagues used amyloid nanowires in
Fig. 5 Self-assembling peptides are promising nanomaterials for the
construction of ultracapacitors to store energy. (a) Self-assembling aromatic
dipeptide nanotubes (ADNTs) can be produced and vertically aligned via the
depicted vapour deposition technique being composed of (b) individual
single peptide nanotubes stabilized via (c) classical stacking interactions
between aromatic moieties of the peptides. (d–f) Top-view of scanning
electron microscopy images of (d) uncoated, (e) ADNT-coated and
(f) carbon-nanotube-coated electrodes showing the deposited material.
(g, h) Ultracapacitors based on the ADNT-coated electrodes can be
fabricated as shown by (g) current density measurements of ADNT-
coated (red line), carbon-nanotube-coated (black line) and uncoated (blue
line) carbon electrodes combined with (h) capacitance density tests of the
ADNT-coated carbon electrodes (adapted with permission).131
Fig. 6 Complex peptide-based structures can be formed via the co-assembly
of two simple peptides, the diphenylalanine peptide and its tert-butyl dicarbonate
(Boc) protected analogue. The distinct architectures range from tubular struc-
tures to beaded strings to nanospheres that are stable, but also reversible
structures under specific conditions (adapted with permission).136
Fig. 7 Self-assembling amyloidogenic peptides can be used for the
development of molecular motors. (a) Combining a metal–organic framework
(MOF) and self-assembling FF peptides allows the building of a ‘‘cage cell’’,
(b) where energy can be stored. In addition, the controlled release of self-
assembling FF peptides (c, d), located inside nanoscaled pores of the energy-
storing-cell, can generate motion. (e) A MOF ‘‘mini boat’’ with a narrow opening
makes the chemical motor motion more efficient. (f) Optical image of the
moving MOF ‘‘mini boat’’. (g) Comparison of the velocity and lifetime of the
movement of the free particle (out of the boat) with the loaded boat. This
strategy paves the way for new applications using molecular self-assembling
peptide systems (adapted with permission).137
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organic photovoltaic devices to enhance the transport properties
(with fibrils acting as a template for donor–acceptor materials).
These promising results greatly expand the promising applications
of amyloid-based nanowires143 and merit further investigations
into the potential uses of amyloid-based nanowires.
3.3. Functional templates and the use of amyloids for
nanosensing
It is possible to functionalize amyloids with ligands such as
fluorophores, antibodies, enzymes or other tags that are suitable
for the desired application. A variety of bioactive molecules can
be employed. In Fig. 8, the concept of the amyloid-based
immobilization of active enzymes is illustrated.
Accordingly, nanostructured films from amyloid fibril-forming
hen egg lysozyme could be generated in a scalable macroscopic
approach, as depicted in Fig. 9.144
The fabricated films made from self-assembling amyloid
protein fibrils showed high rigidity up to 5–7 GPa and a well-
defined order that encouraged the alignment of fluorophores.144
This approach allowed producing well-ordered amyloid films,
functionalized with fluorophores and was easily distinguishable
from non-functionalized films. It demonstrates that amyloidogenic
molecules support the alignment of otherwise unstructured
components (such as fluorophores), which in turn gives rise to
new methods for the bottom-up construction of highly organized
multifunctional materials.
Other breakthrough designs have made use of bifunctional
protein nanowires for the development of highly sensitive
immunoassays.10,145 One exemplary approach, applied to the
detection of pathogen Yersinia pestis, is shown in Fig. 10.
Briefly, two version of the amyloidogenic yeast amyloid
protein Sup35p were designed, one fused with protein G
(Sup35p-G), a protein well-known for its ability to bind to
different mammalian immunoglobulins, the other fused with
another protein, the MPH (methyl-parathion hydrolase) enzyme
(Sup35p-MPH). The two versions of hybrid Sup35p molecules
were co-incubated, resulting in amyloid fibrils with two func-
tionalities, i.e. the ability of protein G to interact with protein G
antibody and the enzymatic activity of MPH. Interestingly,
these mixed Sup35p-MPH–Sup35-G amyloid fibrils (which can
also be understood as protein nanowires) exhibited a high
Sup35p-MPH to Sup35p-G ratio. A dramatic improvement in
the detection threshold was achieved, when the G protein
section of the Sup35p-MPH–Sup35-G amyloid fibrils was
allowed to interact with G protein antibody. The interaction
was measured via the MPH activity. This approach led to a
100-fold enhancement of the detection sensitivity towards the
pathogen Yersinia pestis.10,145 With the aim to obtain an
ultra-sensitive molecular biosensor, an auto-biotinylated
bifunctional protein nanowire (bFPNw) was designed, based
on the same principle and employing also Sup35. Protein G and
a biotin acceptor peptide (BAP) were linked to this de novo
designed structure.145 The rationale for these auto-biotinylated
bFPNws is that they could easily be adapted to existing diagnostics
approaches involving antigen–antibody complexes and enzyme-
based detections in a standard biotin–avidin detection system.
Theoretically, this could greatly enhance the sensitivity of
immune-biosensing, which was indeed observed for Yersinia
pestis detection. A 2000- to 4000-fold increase in sensitivity
compared to classical immunoassays was achieved. Thus, the
auto-biotinylated self-assembled bFPNw molecular biosensors
demonstrate the potential use of self-assembling protein nano-
wires in biosensing. In addition, the same group also showed
that pesticides can be detected via a similar approach.146 A new
type of fluorescent molecular biosensors for the detection of the
pesticide MP was developed by construction of a green fluores-
cent protein (GFP) mutant fused to methyl parathion hydrolase
(MPH). In this setup, MPH is used to detect the pesticide in a pH
dependent reaction that releases H+. Linking MPH to the GFP
mutant allows to detect the enzyme activity by monitoring pH
induced changes in GFP fluorescence. The authors took this
approach to the next level by fusing the MPH-GFP mutant
to Sup35protein nanowires to further increase the response
sensitivity of the molecular biosensor. This approach of fusing
a classical protein biosensor structure to self-assembling protein
nanowires, thereby increasing the response, is a promising new
avenue of research. This same strategy may lead to other
sensitive molecular biosensor systems.
Following on a similar line, Mezzenga and co-workers managed
to fabricate interesting new biodegradable nanocomposite materials,
in particular a graphene-based amyloid nanosensing device inspired
originally by collagen structures.25,147 For the graphene–amyloid
Fig. 8 Amyloid sequences can be combined with active biomolecules B,
namely proteins, to (a) generate hybrid molecules with multi-functionalities.
One such example is (b) joining enzymatic activity, provided by the active
enzyme biomolecule B, with the stability and resistance to proteolysis
provided by the amyloid fibril, represented by the blue arrow. Furthermore,
in this set-up, the amyloid fibril may also provide the option of immobiliza-
tion on a surface.
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fibril composites, the globular milk protein b-lactoglobulin was
used. The protein forms well-defined amyloid fibrils.148–151
This protein is another example for an amyloid fibril that not
necessarily has to be toxic. On the contrary, b-lactoglobulin
from milk is in daily use by millions of people, when their diet
includes the consumption of yoghurt. Combining natural
occurring amyloid nanofibers with graphene that is incompatible
with biological entities, but shows exceptional mechanical and
electronic properties, can create exciting novel hybrid materials.
These materials are conductive, can be degraded by enzymes and
feature enzyme-sensing properties together with shape-memory.
Hence, one can imagine that these hybrid graphene-based nano-
composite materials will give rise to inspiring electronic, micro-
mechanical and biological devices. The methodology followed to
produce the graphene-based nanocomposite nanomaterial is
described in detail in Fig. 11.
Baldwin and colleagues showed that SH3 amyloid forming
sequences linked with soluble cytochrome b562 sequences
resulted in the formation of stable fibrils. Importantly, the
cytochrome section remained fully functional and was able to
bind metalloporphyrins, the biological ligand of cytochrome,
Fig. 9 Well-structured and highly ordered protein films can be produced
from self-assembling amyloid peptides. (a) Amyloidogenic sequences can
self-assemble into amyloid fibrils that are able to form nanostructured
amyloid films by condensation of the fibrillar structures. (b) Atomic force
micrograph of the mature amyloid fibrils from which the (c) free-standing
protein film is derived. The film is stable and visible by scanning electron
microscopy. (d, e) Optical images of plasticizer containing lysozyme
amyloid films under crossed polarizers shows low transmission through
the protein film when the objective polarizer is parallel to the fibril
alignment in the film (left) and maximal transmission at an angle of
45 degrees (right), demonstrating that the fibrils are therefore perfectly
aligned in the film plane. (f) Fluorescence intensity emitted from nano-
structured films containing aligned fluorophores. Emission occurs either
through a polarizing filter that emits light while the film rotates 360 degrees
(filled blue squares) or in the absence of the polarizer (green open squares)
showing that self-organizing protein nanofilms can be used to fabricate
highly organized and perfectly aligned fluorophores-containing amyloid
nanofilms. (g) This is observed in the fluorescence microscopy image
of non-functionalized (left) and functionalized (right) fibril film (adapted
with permission).144
Fig. 10 Amyloids can increase the threshold of current antibody-based
detection of biomolecules. (a–d) Amyloid sequences can be employed to
build a sensitive and easily operable immunoassay based on bifunctional
protein nanowires composed of the yeast amyloid protein Sup35p genetically
fused with protein G and an enzyme (methyl-parathion hydrolase, MPH). The
approach takes advantage of the self-assembling, seeding and nucleation
properties of the amyloidogenic sequences. (e–f) In the final bifunctional
nanowire, the Sup35 acts as the skeleton arraying a few copies of protein G
molecules with a large number of enzyme molecules. It demonstrates a high
ratio of enzyme to protein G molecules that provokes a dramatic increase of
the enzymatic signal when protein G binds to an antibody target. (g) Compar-
ison of the sensitivity of bifunctional protein nanowires, commercial ELISA
reagent, and MPH-protein G chimera for Yersinia pestis F1 antigen detection. At
low concentrations of the antigen, a roughly 100-fold enhancement of the
sensitivity can be achieved, when comparing the detection limit of a classical
ELISA assay with the detection limit reached by the bifunctional protein
nanowires (threshold below 2 ng mL1) (adapted with permission).10,145
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supporting similar approaches for applications in nanotechnology.152
Liu and co-workers also managed to incorporate cytosine, a
nucleobase, into the side chain of the amyloid peptide
HHQALVFFA. This has opened a new avenue of possibilities
via the joint use of amyloid sequences and nucleobases.153
Recently, Münch and colleagues reported that peptides derived
from HIV-1 glycoprotein gp120 that self-assembled to amyloid-
like fibrils could be useful as gene delivery vehicles. They
demonstrated, as exemplified in Fig. 12, that artificial nanofibers
received from a 12-mer peptide, called enhancing factor C
(EF-C), were efficient agents for retroviral ex vivo transduction.154
Interestingly, the positively charged peptide nanofibers
captured the viral particles for viral infection in a much more
efficient way than semen-derived fibrils as well as RetroNectin,
a commercially derived ‘‘gold standard’’ for enhanced retroviral
gene transfer. Furthermore, the EF-C fibrils were stable at room
temperature or 4 1C for at least two weeks without compromising
infection-enhancing activity. They also displayed high stiffness.
Positive net charges can easily be introduced into peptide
sequences by choosing the correctly charged amino acid resi-
dues which enables the nanofibrils to capture nucleic acids,
such as DNA or RNA and promotes the attachment and fusion to
target cellular membranes. Thus, novel gene transfer vehicles
from short amyloid-like peptides could offer interesting new
avenues. Rao and co-workers employed bovine insulin to make
amyloid fibrils functionalized with poly(vinyl alcohol) (PVOH)
resulting in a PVOH-amyloid composite stiffer than the amyloid-
free version although it contained only 0.6% (weight) of peptide
material.155 This validates and serves as a proof-of-concept of the
use of amyloid fibrils in films of polymeric materials to vary their
mechanical/morphological properties.
The design of biologically functional surfaces was per-
formed by Grass and colleagues employing transthyretin
(TTR) amyloid fibrils as modulating biomaterial for promoting
and exploiting cell adhesion, migration and differentiation
in vitro.3 Briefly, they have shown that TTR peptide sequences
combined with a biological cell adhesion motif sequence self-
assembles in aqueous solution to form amyloid fibrils. These
fibrils are bioactive with cells being able to interact specifically
with the RGD group displayed on the fibril surface. These
exciting findings points to a number of possible variations,
where de novo engineered amyloid-containing surfaces can be
created to exert specific interaction properties with a wide
variety of cell types. Moving forward on this subject, Kasai
and colleagues revealed that another amyloidogenic peptide,
the A208 peptide, that contains N-terminal sequences of mouse
laminin 1,156 is able to form amyloid gels. Laminin 1 is involved
in cell adhesion, migration, neurite outgrowth, tumor meta-
stasis, and angiogenesis.143 In fact, it is this amyloid fibrillar
form that promotes cell attachment via the bioactive laminin
section. Other studies with insulin-based amyloid peptides also
supported this approach.157 Summarized, these results clearly
suggest a role for multifunctional peptide fibrils as bioadhesives
for tissue regeneration and engineering.
Amyloids may also have a role in cell differentiation, namely
with IKVAV peptide, another very promising peptide for amyloid
applications.158–163 The peptide IKVAV corresponds to the
neurite-promoting laminin epitope, which, when constituted
into nanofibrils has been shown to induce very rapid differentia-
tion of cells into neurons, at a better rate then soluble or peptide
or laminin itself.156,158 Hauser et al. have rationally designed a
class of ultrashort aliphatic peptides containing 3–7 amino acids
that have an innate ability to self-assemble to amyloid-like
helical nanofibers. These fibers ultimately form hydrogels. Due
to their small size these peptides are attractive, since they offer a
cheap production alternative to other protein or peptide-based
structures with longer sequences.106,164 In a recent study,165 the
integrin-recognition motif RGD was conjugated to the hexamer
peptide Ac-LIVAGKC (LK6C) and afterwards cysteine-mediated
disulfide bonds were introduced to the nanofibers assembled
from the hexamer. The bioactive RGD motif visibly supported
Fig. 11 Graphene material and self-assembling amyloid peptides can
generate structures that are able to sense enzyme activity. (a–d) Schematic
representations show the fabrication of free-standing films of amyloid
fibrils–graphene composites. (a) Self-assembly of b-lactoglobulin into
amyloid fibrils is accomplished through (b) electrostatically driven
co-aggregation of amyloid fibrils and graphene oxide. (c) The binding of
broken amyloid fibrils on graphene surfaces during reduction of graphene
oxide forms (d) layers of amyloid fibrils and graphene nanosheets hybrid
nanocomposites. (e) Transmission electron microscopy and (f) atomic
force microscopy images of reduced graphene dispersions at pH 2 with
a 1 : 8 graphene–amyloid fibril ratio demonstrating the formation of stable
amyloid–graphene films that can remain conjugated and stable for several
weeks. (g) The hybrid nanocomposite films can be used to develop a
biosensor with enzyme activity as depicted in the inset. When incorporat-
ing a desired protein, namely pepsin at 1%, it can detect the difference
between folded and unfolded protein (adapted with permission).147
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cell viability and spreading in a true 3D distribution.165 These
cross-linked 3D matrices made from amyloid nanofibers can
easily be envisioned for further applications delivering thera-
peutics and other compounds, as depicted in Fig. 13. In a recent
paper, Loo et al. showed that lysine-containing ultrashort
amyloid-like peptides can be used as hydrogels for wound
dressings to address unmet clinical needs in the treatment of
partial thickness burns. The nanofibrous hydrogels accelerated
wound closure in a rat model for partial thickness burns.
Furthermore, the amyloid hydrogels effected earlier onset and
completion of autolytic debridement compared to the control,
used as a standard-of-care.166 The ultrashort aliphatic amyloid
peptides were further explored for localized injectable anti-
cancer therapy. The peptides were functionalized with platinum
anti-cancer drugs and oxaliplatin-derived hybrid peptide hydro-
gels with up to 40% drug loading were tested for localized breast
cancer therapy in a mouse model. Stably injected gels showed
significant tumor growth reduction and a better tolerance com-
pared to the free platinum drug.167
In peptide constructs such as those formed by a bioactive
peptide plus an amyloid peptide, a major advantage for appli-
cations would be that the kinetics of amyloidogenesis can be
adjusted via subtle changes in the amyloid peptide sequence.
Hence, for a particular clinical use, peptide sequence might be
altered, while the nanofibrils bioactivity is maintained.159
Mutation of the peptide sequence by including more hydro-
philic and bulky amino acids effectively slows down gelation
through self-assembly of the nanofiber network. The ability to
Fig. 12 Amyloid fibrils can be employed as enhancers of retroviral transduc-
tion increasing gene transfer in mice models. (a–d) Amyloid fibrils, formed from
a self-assembling 12 amino acids peptide named enhancing factor C (EF-C),
are transduction enhancers. (a) Inoculating HeLa cells (blue) with viral particles
with the MLV glycoprotein labelled with yellow fluorescent protein (MLV-YFP,
green) in the absence (top line of the panel) of rhodamine-labelled fibers
(Rho-EF-C, red) or in the presence of the labelled fibers shows that the
presence of the fibers, which are not cytotoxic, enhances viral replication.
(b) Quantitative comparison of the fibril effect in the increase of the virions rate
of fusion with cells. (c) EF-C fibrils increase lentiviral transduction of 293T cells
independently of the viral glycoprotein. (d) EF-C fibrils mediated lentiviral gene
transfer is effective with several different cell types, namely human glioblastoma
(U87MG), endocrine pancreatic tumour (BON), myeloid KG-1, peripheral blood
mononuclear (PBL) and haematopoetic (CD34) stem cells. Importantly, EF-C
fibrils can be immobilized (e–g) and allow efficient gene transfer into mice
(h–j). (e) Z-stack images of immobilized Rho-EF-C fibrils only (top left), MLV-
YFP only (bottom left) and immobilized Rho-EF-C fibrils exposed to virus (right;
the upper image shows both channels, merged, and the lower images,
separately). (f) EF-C fibrils coating facilitates lentiviral infection in a degree
similar to an established standard method based on (g) RetroNectin (RN) which,
(h) if put together possess an additive effect to each other. (i) EF-C fibril coating
also prompts lentiviral gene transfer to mouse cells. (j) Treating bone marrow
cells with the EF-C amyloid fibrils and transducing them with a GFP-labeled
lentiviral vector before transplanting the cells into recipient mice results in a
high success rate with a number of GFP-positive cells in peripheral blood,
demonstrating that EF-C amyloid fibrils facilitate retroviral gene transfer
(adapted with permission).154
Fig. 13 Amyloidogenic peptides serve as novel three-dimensional (3D)
substrates suitable for tissue engineering applications. (a) HepG2 cells
were seeded either directly onto wells (2D control) or onto gels (3D)
containing LK6C (an amyloidogenic peptide) with different concentrations
of conjugated integrin recognition motif RGD (CRGD). Cells proliferated in
a 3D environment within the gel while the RGD motif enhanced cellular
attachments. (b) After 4 days in culture the cells remained viable as
evidenced by the calcein incorporation assay. (a) Visual inspection of
HepG2 cultured cells suggested that CRGD-functionalized amyloidogenic
peptide gels increased cell viability, as further demonstrated (c) quantita-
tively via the MTT cell viability assay. (d) Using 3D-LK6C in absence or
presence of CRGD and comparing it with the 2D-control gave no
significant difference on the cell spreading area. Overall, this suggests
new pathways for cell culture and tissue engineering by jointly exploring
the 3D patterns created by different amyloidogenic peptides and the ability
to functionalize them with several biologically relevant molecules (adapted
with permission).165
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modify gelation kinetics in self-assembling systems without
disrupting bioactivity is an important aspect for the development of
injectable therapies in regenerative medicine. Feasible strategies
for novel therapeutic approaches using self-assembling peptide
nanofibers for angiogenesis and cardiac repair can be envisioned
when reading the study of Lin et al., 2012.168 Peptide nanofibers
mixed with vascular endothelial growth factor (VEGF) were injected
into the heart of rats or pigs. Interestingly, the increased densities
of arteries and arterioles after injection pointed to neovasculariza-
tion. Furthermore, endogenous myofibroblasts and cardiomyocyte-
resembling cells were newly recruited. These and other studies
might encourage the use of amyloid nanofibers for future clinical
translational applications, for injectable therapies such as
cardiovascular repair and other regenerative treatments.
4. Challenges and future directions
The potential of proteins or peptides to form irregular protein
aggregates or highly structured amyloid fibrils, although ultimately
present in the polypeptide chain, varies strongly.35,108,169,170 The
rational design of a de novo amyloid sequence, unrelated to any
known amyloidogenic protein, is extremely challenging due to the
complexity of the formation of amyloid fiber structure, including
intermediate structures. Although the final structural properties of
amyloid fibrils are highly similar, it is so far still impossible to
predict the amyloid propensity from a given peptide sequence that
is for example able to form beta-sheet structures. The reason for
this dilemma is comprehensible in view that the mechanism of
amyloid formation is far from being understood. Hence, it is not
simply possible to assume that all existing or imaginable self-
assembling peptide systems that are able to form beta-sheets or
beta-turns are necessarily forming amyloid fibrils. The question
remains which sequence of a self-assembling peptide monomer
qualifies most likely to the formation of proper amyloid fibrils.
Thus, we suggest referring best to the unequivocally and
meticulously elaborated structural data set that were gained
by Serpell and colleagues from natural occurring proper
amyloid fibrils via X-ray analysis.21–24 The reported typical
cross-beta diffraction data have given so far the most unifying
answer in terms of characterization of all known amyloid
structures. The cross-beta diffraction pattern generally exhibits
a longitudinal 4.7–4.8 Å spacing and an equatorial spacing of
around 10 Å. The term ‘‘cross-beta’’ refers to both diffraction
signals, the longitudinal and the equatorial spacing, that form
a typical cross pattern. Ideally, this should be taken as the gold
standard to define and unmistakably classify amyloid fibrils.
Several factors must be weighed in for the successful design of
novel functional amyloid-based nanomaterials. The main
aspects to take into consideration are described in Fig. 14.
Evidently, an important aspect is the analysis of the amino
acid sequence of the amyloidogenic peptide or protein in
question. The process of amyloid formation has similarities
with the folding process, in the sense that it is highly ordered
and ultimately governed by the primary protein sequence.
In the case of hexapeptides, ideally, this should allow to use
simple scoring matrices with information regarding only
primary structures that predict the amyloid propensity.108
The finding that the amyloid fibrils precursors (but not the
fibrils themselves) are the cause for toxicity led to the careful
characterization of the process of amyloidogenesis, i.e., the
evolution from the peptide or protein monomers stage, to the
precursor intermediates (where a multitude of species such as
oligomers and protofibrils may be present), to, finally, arrive at
the mature amyloid fibril stage.35,107,108,115,169,170 It is generally
agreed that a key mechanism to fibril formation is the nuclea-
tion event.115,169,171 Initially, there is a lag phase, during which
monomers self-assemble into higher order aggregates, which
form the seeding nucleus. The process will then further
Fig. 14 Main factors to consider for the assembly of amyloid fibers.
Amyloidogenic peptides and proteins that are suitable for amyloid fiber
formation can be used for the insertion of new functions into the mature
amyloid fibrils. Several factors are pivotal to successfully engineer amyloid
fibers. To predict the amyloid propensity and functionality of a newly
designed peptide sequence is a major hurdle. Modifying or adding func-
tionality to an already known amyloid sequence might severely impact its
amyloid propensity and functionality. Controlling the speed and moment
of fibrilization/nucleation is another factor to be considered. Once these
obstacles are surpassed, determining the engineered fibrils’ putative toxi-
city, their stability in different environments and their ability to perform the
designed function are the final steps for successful manufacturing novel
amyloid-based biomaterials. The schematic drawing of an antiparallel
amyloid monomer arrangement is only used as a showcase, since there
are parallel monomer arrangements possible as well.
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progress in an extremely fast manner by the addition of other
nuclei or monomers, resulting in the formation of protofibrils and
amyloid fibrils. However, the kinetics and amyloid morphology of
related and almost identical peptides, such as the amyloid beta
peptide 40 (Abeta40) and the amyloid beta peptide 42 (Abeta42),
involved in Alzheimer’s disease and differing in only two amino-
acids, can be significantly different.169 Therefore, it would give
major advantages for amyloid-based nanotechnology to predict
the amyloid propensity. This will be discussed in the following,
together with the issues regarding the control of the amyloido-
genesis process and of the eventual problem of fibril toxicity.
4.1. Predicting amyloid propensity and peptide design
The issue of predicting the potential of peptide sequences that form
amyloid fibers is a hot and problematic research topic. There have
been continuously improvements by different groups over the years.
The approaches range from special physico-chemical property win-
dows to position-specific sequence matrices, explicit structural
models, and combinations thereof.108,116,172–185 Many methods base
their prediction on the potential of hexapeptides to form amyloid
fibres. This characteristic length has been found to cover several of
the core motifs for amyloid fiber formation. Of course, fiber forming
properties are not restricted to hexameric peptides alone. In fact,
amyloid core sequences span sizes from four to seven amino acids,
as earlier discussed.
Currently, the sequences known to form amyloid fibers are
still relatively narrow in terms of amino acid coverage for each
position and partially dominated by well-studied peptide families
with high internal similarity. Consequently, sequence-based
prediction of effects of selected point mutations to increase or
decrease amyloid propensity for peptide design should work best
for peptide scaffolds with sufficient related positive and negative
known examples. Structural methods on the other hand are less
affected by peptide family bias. These methods suffer from
giving just a partial success rate of accurately describing all
acting molecular forces in fiber structures. This includes solva-
tion and entropic effects as well as limitations in timescales for
conformational sampling through simulations.
Although approaches combining sequence, physico-chemical
property and structural terms tend to perform best overall, there
is sufficient diversity among available methods that could result
in divergent predictions in specific cases. However, another
critical aspect for successful peptide design of amyloid fibers is
the distinction of ordered amyloid fibers versus unordered
amorphous beta aggregation, as discussed earlier. The delicate
balance can be explored by combined use of prediction tools like
Tango and Waltz.186 Tango is based on physico-chemical prin-
ciples of beta-sheet formation and well-suited for distinguishing
soluble from hydrophobic aggregating sequences.174 Waltz, on
the other hand, is specialized on the specific ordered amyloid
fibers108 which can be formed both by polar and hydrophobic
peptides. Together, they elegantly complement each other.
For example, Tango could be used on Waltz predictions to
filter candidates which may be too hydrophobic and form fast
amorphous aggregates instead of fibers.
Ultimately, peptide candidates predicted from any in silico
approach still need to be experimentally characterized for
amyloid fiber formation and further tested for suitability as
nanomaterial. The expected hit rate of predicted peptides to
actually form fibers currently lies around 50–80%. However, if
one were to attempt to cover the whole sequence space by
testing for example all possible hexapeptides, a peptide of
length 6 and an alphabet of 20 amino acids would allow
64 000 000 possible sequences. Therefore, computational prediction
appears indispensable to narrow down and identify a manageable
number of candidates for experimental testing.
Interestingly, in the case of hexapeptides it turns out that
nature did not sample the sequence space completely. For
example, in the human proteome (IPI v3.5 nr100) only about
14% of all theoretically possible hexapeptides actually are
found to occur naturally. Such peptide sequence space under-
sampling of longer peptides is also seen in all other proteomes
from eukaryotes to bacteria187 and hence appears to be mainly
a matter of the limited time that DNA-based organisms had so
far for their evolution. At the same time, a strong biophysical
phenomenon such as amyloid fiber formation should also have
an impact on the fitness of an organism and on natural
selection as was shown for beta aggregation and diseases.188
Consequently, peptide design efforts should not neglect the
huge pool of peptides that do not naturally occur as it could be
the source of yet to be discovered strongly amyloid forming
peptides. A prime example for an unnatural amyloid system is
the class of ultrashort aliphatic peptides. All peptides of this
class do not correspond to any known sequence of a natural
protein, but were rationally designed.118,164 Other peptide
systems that adopt typical beta-sheet structures have been
developed, for example by J. Collier, A. Aggelli, D. Pochan and
others, discussed in a recent review.36
4.2. Controlling nucleation-dependent amyloidogenesis
Despite significant differences in symptoms or functions as
well as in the actual sequence of the protein monomers
associated with the specific amyloid fibrils, there seems to be
a common mechanism underlying protein aggregation at the
molecular level as well as a common ordered structure, i.e. the -
turn structure, of the involved aggregated amyloid proteins.
There have been several models emerged that give mechanistic
explanations on the formation of the amyloid protein aggre-
gates.189 A simple model defines the polymerization as a
nucleation-dependent mechanism, controlled by monomer
concentration and time. The formation of amyloid fibrils
occurs through a molecular recognition and self-assembly
process that typically starts with a thermodynamically unfa-
vourable lag phase for the formation of a ‘nucleus or seed’. This
is followed by a thermodynamically favourable exponential
growth phase, where monomers/oligomers are added to the
growing nucleus. A related concept stresses the significance of
polymerization by fibril seeding. Structural investigations on
amyloidogenic core sequences, peptides of the size of 3–7 amino
acids, have revealed conformational transition of the peptides from
a random-coiled soluble form via possibly a-helical intermediates
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into insoluble, cross b-pleated fiber aggregates.190 These a-helical
intermediates are thought to be a key event in amyloidogenesis.106
While recent investigations have focussed on the mechanism of
molecular recognition and self-assembly in amyloidogenesis in order
to inhibit this process, there are so far no effective preventions or
treatments for any of these diseases available. Nonetheless, different
concepts have been proposed. Therapeutic compounds, such as
small molecules, that safely antagonize and prevent amyloidogenesis
are desperately needed. The anti-amyloidogenic candidates should
also be able to fulfil stringent requirements, such as efficient and
easy uptake, sufficient half-life and circulation time in vivo, non-
toxicity, and permeability through the blood–brain barrier (BBB),
which is needed when treating neuro- or other degenerative condi-
tions. Furthermore, since there is increasing evidence that pre-fibril
oligomer intermediates may be even more toxic than mature
amyloid fibers, it is important to arrest or reverse the self-assembly
process at an early stage.
4.3. Balancing fibril toxicity
As described in detail in the previous sections, amyloid fibrils are
essentially self-assembled protein–peptide aggregates that reveal
ordered cross-ß, also termed ß-turn structures.24,31,37,39,40 Amyloid
fibrils have known fundamental roles in biological processes.
Fibril formation is a key event in diverse and structurally
unrelated pathological processes that can be broadly classified
as neurodegenerative, e.g., Alzheimer’s, Parkinson’s, Huntington’s,
or non-neuropathic localized amyloidosis (such as in type II
diabetes) and systemic amyloidosis (that occurs in multiple
tissues), collectively ‘‘called amyloid diseases’’.101 On the con-
trary, amyloid fibrils may also have a function in signalling,
communication and memory-storage, as described above. Thus,
although we generally tend to associate amyloid fibrils with the
likelihood of being toxic, as featured in the mentioned diseases,
this is not fully justified. As discussed above, functional amyloid
fibrils contribute to cellular biological tasks which include biofilm
formation,2,97 structural scaffolds,191 adhesives,192 long-term
memory99 and hormone storage89 among other proposed roles.
Furthermore, it was already earlier proposed that the self-
assembly process into amyloid structures is a generic process
that may occur for more or less every polypeptide, if the condi-
tions are prone to it.85,193 As such, fibril formation is neither
necessarily pathological nor an extremely rare possible confor-
mation for an amino acid sequence. Often mentioned examples
are human lysozyme and human serum albumin that convert to
amyloid aggregates under certain conditions.94,95 If the transfor-
mation from a non-amyloid to an amyloid variant is a true
event in physiology, the amyloid structural motif could point
to an important inherent property of proteins, representing one
generic form of the protein. The question remains, how we can
foresee, if the amyloid fibrillogenesis is for better or for worth. In
some cases, such as for human lysozyme, the amyloid variant
is actually cytotoxic and found in patients with systemic
amyloidosis, known as non-neuropathic systemic lysozyme
amyloidosis and responsible for hepatocyte death.194 In other
cases, as for human protein Pmel17 (discussed in Fig. 3), the
amyloid fibril is an example for a functional amyloid that plays a
role in the polymerization of the pigment melanin, needed for skin
pigmentation in mammals. Here, the Pmel17 amyloid fibers,
found in melanosomes, serve as a template for the polymeriza-
tion of the pigment melanin.92 Hence, Pmel17 strikes a remark-
able balance, being a non-pathological functional amyloid in
humans. Also, the peptide hormones corticotropin-releasing
hormone (CRH), human prolactin (hPRL), and somatostatin,
the growth hormone inhibitor hormone (GHIH), are other
examples that transform at high concentrations into amyloid
fibrils.89,195 It is not yet understood how these hormones,
assembled to amyloid fibrils, get packed into intracellular
neuronal secretory vesicles. In all these cases, the amyloid fibers
are serving vital cellular functions. Besides the question what
determines the fate of an amyloid fibril to be a good performer,
serving well in cellular physiology, or being the spoiling one,
responsible for a multitude of devastating diseases with Alzhei-
mer’s, Parkinson’s, (Amyotrophic lateral sclerosis) ALS, diabetes
type 2 as the mostly mentioned ones, there is the unsolved
question on the stability of an amyloid fibril per se. Are the fibril
structures irreversibly associated within the fiber network or are
the amyloid aggregates in equilibrium with their polymeric and
monomeric entities? The latter would mean that the fibril
formation is a reversible process and can be shifted back to
the starting conditions when the self-assembly from the mono-
mer building block started. This is not only of academic interest,
since it has crucial relevance when assessing fibril toxicity. The
most prominent examples, where a reversible process from
fibrils back to monomers is assumed, are the amyloid fibrils
from peptide hormones that are stored in pituitary secretory
granules.89,195 Here, the fibrils are protected and surrounded by
a membrane within the vesicles. If the storage of the amyloid
fibrils in vesicles has practical reasons to guarantee a controlled
secretory release or if the enclosure gives further protection to
hinder a toxic disease-related aggregation of peptide hormones
is elusive. Interestingly, peptide hormones are involved in patho-
logical conditions, such as calcitonin associated with thyroid
medullary carcinoma, amylin in diabetes type 2 and atrial natriure-
tic factor in atrial amyloidosis.86 There might be a delicate balance
between the healthy and the toxic state of a polypeptide. In most
cases, it is assumed that the fibrils, once matured and if not
perturbed by destabilizing agents, such as lipids for example,107 are
essentially stable and will not return to the toxic state.
To avoid potential toxicity, amyloid fibril design for use at
the human interface should refrain from any peptide sequences
involved in known diseases. The peptide design should be
coupled to emerging computational approaches. Also, immu-
nogenicity of peptides for innate, T cell and B cell immune
responses should be carefully monitored.196 Fortunately, as
described above, it is now clear that mature amyloid fibrils
are not the most cytotoxic species. This applies likewise to the
pathological fibril formation processes. If the equilibrium is
shifted towards stable amyloid fibrils, most of toxicity concerns
do not apply. Therefore, amyloid-based nanotechnology
approaches should ideally focus on the use of mature amyloid
fibrils, which, are also the most stable and feasible species to
work with.
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5. Conclusions
Exploring amyloids for applications in nanotechnology will open
up new strategies for future developments regarding applications
in nanomedicine and engineering. We have discussed some of the
exciting recent achievements that target biomedical therapies,
biosensing, disease diagnostics, biomarker screening, bioimaging
and monitoring. The challenge remains to have the ultimate
control over the final amyloid structures by precisely steering the
design on a molecular level, enabling technological manipulation
through structural fine-tuning and guaranteeing an accurate per-
formance when in use. Recent progress supports the assumption
that the current concerns will be overcome as the field matures,
paving the way to further advances in the development of novel
amyloid-based nanotechnology approaches.
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